Roadmap™ Analysis
AI-assisted reading of Coronary CTA scans
ApprovedCommercial
Key Facts
About HeartFlow
HeartFlow's mission is to transform coronary artery disease (CAD) from the leading cause of death into a manageable condition for life. The company leverages a proprietary AI-powered platform to analyze CCTA scans, generating non-invasive fractional flow reserve (FFRCT) measurements, plaque quantification, and anatomical roadmaps to guide patient care. With over 600,000 patients treated, 1,800+ institutions using its technology, and a robust clinical evidence base of 600+ peer-reviewed publications, HeartFlow is establishing itself as a leader in precision cardiovascular diagnostics. The company is headquartered in San Francisco, California, and operates globally.
View full company profile